Foreword: Preventing COVID-19 Among the Immunocompromised Population

Area of Science:

• Immunology
• Public Health
• Infectious Diseases

Background:

• The COVID-19 pandemic posed unique public health challenges, especially for immunocompromised individuals at high risk of SARS-CoV-2 infection and severe outcomes.
• Initial COVID-19 vaccine trials excluded immunocompromised populations, necessitating post-approval evaluations of vaccine safety, immunogenicity, and real-world effectiveness in this group.

Purpose of the Study:

• To characterize mRNA-based COVID-19 vaccination strategies for immunocompromised individuals.
• To focus on adaptive approaches addressing ongoing challenges in this population during the evolving pandemic.

Main Methods:

• Review and synthesis of emerging immunogenicity data for COVID-19 vaccines in various immunocompromised states.
• Analysis of adapted vaccination strategies, including dosing and timing, based on real-world evidence.

Main Results:

• Vaccination strategies were modified based on immunogenicity data to optimize protection for immunocompromised individuals.
• Ongoing research and adaptation are crucial as the pandemic evolves.

Conclusions:

• Tailored COVID-19 vaccination strategies are essential for effectively protecting immunocompromised individuals.
• Continued evaluation and adaptation of vaccine approaches are necessary to address the evolving pandemic and protect vulnerable populations.